173 related articles for article (PubMed ID: 37350966)
21. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
[TBL] [Abstract][Full Text] [Related]
22. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
Hodi FS; Hwu WJ; Kefford R; Weber JS; Daud A; Hamid O; Patnaik A; Ribas A; Robert C; Gangadhar TC; Joshua AM; Hersey P; Dronca R; Joseph R; Hille D; Xue D; Li XN; Kang SP; Ebbinghaus S; Perrone A; Wolchok JD
J Clin Oncol; 2016 May; 34(13):1510-7. PubMed ID: 26951310
[TBL] [Abstract][Full Text] [Related]
24. Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group.
Nakajima EC; Simpson A; Bogaerts J; de Vries EGE; Do R; Garalda E; Goldmacher G; Kinahan PE; Lambin P; LeStage B; Li Q; Lin F; Litière S; Perez-Lopez R; Petrick N; Schwartz L; Seymour L; Shankar L; Laurie SA
JCO Precis Oncol; 2024 Apr; 8():e2300687. PubMed ID: 38635935
[TBL] [Abstract][Full Text] [Related]
25. Objective response rate assessment in oncology: Current situation and future expectations.
Aykan NF; Özatlı T
World J Clin Oncol; 2020 Feb; 11(2):53-73. PubMed ID: 32133275
[TBL] [Abstract][Full Text] [Related]
26. Payer perceptions on the use of patient-reported outcomes in oncology decision making.
Oderda G; Brixner D; Biskupiak J; Burgoyne D; Arondekar B; Deal LS; Quek RG; Niyazov A
J Manag Care Spec Pharm; 2022 Feb; 28(2):188-195. PubMed ID: 34806908
[No Abstract] [Full Text] [Related]
27. The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies.
Cirkel GA; Weeber F; Bins S; Gadellaa-van Hooijdonk CG; van Werkhoven E; Willems SM; van Stralen M; Veldhuis WB; Ubink I; Steeghs N; de Jonge MJ; Langenberg MH; Schellens JH; Sleijfer S; Lolkema MP; Voest EE
Ann Oncol; 2016 Aug; 27(8):1638-43. PubMed ID: 27234642
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database.
Ou FS; Ahn DH; Dixon JG; Grothey A; Lou Y; Kasi PM; Hubbard JM; Van Cutsem E; Saltz LB; Schmoll HJ; Goldberg RM; Venook AP; Hoff P; Douillard JY; Hecht JR; Hurwitz H; Punt CJA; Koopman M; Bokemeyer C; Fuchs CS; Diaz-Rubio E; Tebbutt NC; Cremolini C; Kabbinavar FF; Bekaii-Saab T; Chibaudel B; Yoshino T; Zalcberg J; Adams RA; de Gramont A; Shi Q
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627145
[TBL] [Abstract][Full Text] [Related]
29. Optimal decision-making in oncology development programs based on probability of success for phase III utilizing phase II/III data on response and overall survival.
Götte H; Xiong J; Kirchner M; Demirtas H; Kieser M
Pharm Stat; 2020 Nov; 19(6):861-881. PubMed ID: 32662598
[TBL] [Abstract][Full Text] [Related]
30. Next generation immuno-oncology tumor profiling using a rapid, non-invasive, computational biophysics biomarker in early-stage breast cancer.
Cook D; Biancalana M; Liadis N; Lopez Ramos D; Zhang Y; Patel S; Peterson JR; Pfeiffer JR; Cole JA; Antony AK
Front Artif Intell; 2023; 6():1153083. PubMed ID: 37138891
[TBL] [Abstract][Full Text] [Related]
31. ctDNA-Response evaluation criteria in solid tumors - a new measure in medical oncology.
Jakobsen AKM; Spindler KG
Eur J Cancer; 2023 Feb; 180():180-183. PubMed ID: 36610263
[TBL] [Abstract][Full Text] [Related]
32. Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer.
Wang H; Ma H; Sové RJ; Emens LA; Popel AS
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579739
[TBL] [Abstract][Full Text] [Related]
33. A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics.
Yu J; Wang N; Kågedal M
CPT Pharmacometrics Syst Pharmacol; 2020 Mar; 9(3):177-184. PubMed ID: 32036626
[TBL] [Abstract][Full Text] [Related]
34. Discrepant Assessments of Progressive Disease in Clinical Trials between Routine Clinical Reads and Formal RECIST 1.1 Interpretations.
Siegel MJ; Ippolito JE; Wahl RL; Siegel BA
Radiol Imaging Cancer; 2023 Sep; 5(5):e230001. PubMed ID: 37540134
[TBL] [Abstract][Full Text] [Related]
35. Virtual Populations for Quantitative Systems Pharmacology Models.
Cheng Y; Straube R; Alnaif AE; Huang L; Leil TA; Schmidt BJ
Methods Mol Biol; 2022; 2486():129-179. PubMed ID: 35437722
[TBL] [Abstract][Full Text] [Related]
36. [Comparison of RECIST 1.1 and iRECIST for Response Evaluation in Solid Tumours].
Houdek Š; Büchler T; Kindlová E
Klin Onkol; 2017; 30(Supplementum3):32-39. PubMed ID: 29239190
[TBL] [Abstract][Full Text] [Related]
37. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.
Hodi FS; Ballinger M; Lyons B; Soria JC; Nishino M; Tabernero J; Powles T; Smith D; Hoos A; McKenna C; Beyer U; Rhee I; Fine G; Winslow N; Chen DS; Wolchok JD
J Clin Oncol; 2018 Mar; 36(9):850-858. PubMed ID: 29341833
[TBL] [Abstract][Full Text] [Related]
38. Towards integrative systems pharmacology models in oncology drug development.
van Hasselt JG; van der Graaf PH
Drug Discov Today Technol; 2015 Aug; 15():1-8. PubMed ID: 26464083
[TBL] [Abstract][Full Text] [Related]
39. Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib.
Ulaner GA; Saura C; Piha-Paul SA; Mayer I; Quinn D; Jhaveri K; Stone B; Shahin S; Mann G; Dujka M; Bryce R; Meric-Bernstam F; Solit DB; Hyman DM
Clin Cancer Res; 2019 Dec; 25(24):7381-7387. PubMed ID: 31548342
[TBL] [Abstract][Full Text] [Related]
40. Shared decision making in oncology practice: what do oncologists need to know?
Politi MC; Studts JL; Hayslip JW
Oncologist; 2012; 17(1):91-100. PubMed ID: 22234632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
